Prolocor raises $1.7 million for an accurate thrombosis risk diagnostic program

Prolocor, Inc., a Philadelphia healthcare startup, announces it has raised $1.7 million in bridge funding. This sum will be used to continue the clinical development and commercialization, planned for 2024, of a precise diagnostic test intended to predict the risk of thrombosis. This funding saw notable participation from Green Park & Golf Ventures and Labcorp Venture Fund.

Prolocor's innovative test, called pFCG, promises to improve the prognosis of thrombotic risk by quantifying FcγRIIa on fixed platelets. The company has already completed the enrollment of 800 patients for its acute coronary syndrome trial across 25 nationally recognized hospitals and completed an interim analysis in September 2023.

Prolocor's efforts to develop this prognostic tool represent a significant advance in the management of patients suffering from chronic coronary artery disease. More than 50 million people are affected in regions including the United States, Europe and Japan, with more than two million cases of acute coronary syndrome per year.